for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tibet Rhodiola Pharma obtains right to develop Russia's Sputnik-V vaccine in China

HONG KONG/BEIJING, Nov 11 (Reuters) - Chinese firm Tibet Rhodiola Pharma holding said on Wednesday that it has obtained non-exclusive right to develop, manufacture, import or commercialize Russia’s COVID-19 vaccine, Sputnik V, in mainland China, Hong Kong, Macau and Taiwan.

The Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, Russia’s sovereign wealth fund said earlier, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

Reporting by Meg Shen and Roxanne Liu, editing by Louise Heavens

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up